Background: Evidence suggests that patients afflicted with COVID-19 are subject to significant risks of thromboembolic complications. We aimed to evaluate the occurrence of coagulation disorders in patients suffering from COVID-19 and determine its relationship with the disease outcome. Methods: This cross-sectional study was conducted on 106 COVID-19 patients who were hospitalized in Imam Khomeini Hospital, Ardabil, Iran. After the preliminary completion of the information forms, 3 cc of intravenous blood sample was taken from each of the patients to check the patients’ INR, PT, CBC, and D-dimer. The patients were monitored. Finally, the results obtained from these clinical assessments and tests were all recorded in checklists and statistically analyzed using SPSS Software, Version 19. Results: Of the total 106 COVID-19 patients who entered the study, 69 cases were discharged from the hospital alive while the other 37 cases died. The mean age of the patients was 58.99±15.94 years and 56.6% of them were male. There were significant differences between the survived and the deceased patients in terms of D-dimer, LDH, PT, and INR levels (p<0.05). Based on the results of logistic regression analysis, only D-dimer was found to have a significant effect on predicting mortality. More specifically, with the increase of each 1 unit in D-dimer level, the mortality risk increased by 0.99%. Conclusion: D-dimer has a higher sensitivity in comparison with other markers of coagulation and is of relatively greater value in terms of intensity. Compared to the high prevalence of thrombotic events, bleeding is not that common; therefore, standard anticoagulant therapy is highly recommended.